First Digital Health Osteoarthritis Wearable Glove System Starts Pre-launch Pilot Trial Series & Medical Tests

MADRID, Sept. 30, 2019 /PRNewswire/ — QUANTIC NANOTECH, a product division of Spanish DEMAC S.A. group who presented the first home wearable osteoarthritis treatment glove system “QNANO GLOVE” during the last CES 2019 Edition in Las Vegas, announced today the opening of free treatment sign-up registration for a new medical pre-launch pilot trial series for patients in selected hospitals in Madrid. Due to high demand, this new period is open for any user during a limited period until October 15th, 2019 (HIPAA certified secure server in AWS cloud).

Dr. Luis F. Villa, M.D., Rheumatology consultant at University Hospital Puerta de Hierro Majadahonda in Madrid said: 

‘This device attracted our attention because it allows home application in the affected hand of different therapies of evidence-based proven clinical efficacy, during rest or at night’.

And also declared:

“The treatment of hand osteoarthritis is cumbersome and resource consuming, relying on physical assisted therapy and topical and oral medications. We are interested in the results of the pilot studies, since a home-based device for multimodal physical therapy could make it easier and cheaper for the treatment of patients with this frequent condition’.

Quantic Nanotech therapeutic all-in-one glove integrates revolutionary technologies such as shape memory alloys (SMA) and state-of-the-art materials for appliance of dry heat therapy, vibration, massage as well as stretching and extension of the fingers both active and passively. It also allows the administration of topical medications such as non-steroidal anti-inflammatory drugs (NSAID), liniments and neuromodulators.

First conclusion papers of clinical studies in patients with hand osteoarthritis are planned to be reported within Q4 2019 and Q1 2020.

The therapeutic Quantic Glove is simple and compact. It has been designed for use at home, controlled by smartphones or internet and it also allows remote control by health professionals.

The product has been awarded internationally at various shows like InPEX Pittsburgh, etc, and recently it has also won a new 2019 Technology Innovator Award in August 2019 from AI Global Media, UK, 2019 CV-MAGAZINE.

QUANTIC NANOTECH is closing Round A capital raise with aim for rapid worldwide implementation of the product under a patent license model system.

Rheumatism & Osteoarthritis is a very common disease and a major cause of sick leave worldwide, with USD$ 304 Billions of total medical and earning losses just in the US alone – approximately equivalent to 1% of US gross domestic GDP (Source: arthritis.org – 2013).

QUANTIC NANOTECH will be attending GITEX Exhibition in DUBAI Oct 6-10th 2019 in FUTURE STARS area.

About DEMAC S.A QNANOTECH.

About HIPAA 

Logo: http://qwertypanda.healthtechnologynet.com/wp-content/uploads/2019/09/QUANTIC_NANOTECH_Logo.jpg  

Video: https://youtu.be/zQXIRVpriJY  

 

 

View original content:http://www.prnewswire.com/news-releases/first-digital-health-osteoarthritis-wearable-glove-system-starts-pre-launch-pilot-trial-series–medical-tests-300927514.html

SOURCE QUANTIC NANOTECH

Staff

Recent Posts

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health…

37 minutes ago

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- ChemLex, a next-generation AI-for-science company, today announced the establishment…

37 minutes ago

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

16 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

16 hours ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

16 hours ago